Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials

11/2/2009

Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases

10/26/2009

Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene

8/4/2009

Quark Pharmaceuticals to Participate in IBC’s Oligonucleotide Therapeutics: From Concept to Implementation Conference

7/28/2009

Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma

6/9/2009

Quark Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit

5/14/2009

Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage

5/11/2009

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

4/20/2009

Quark Pharmaceuticals Presents at American Society for Pharmacology and Experimental Therapeutics Annual Meeting

3/9/2009

Quark Pharmaceuticals Presents at Asia TIDES Conference

Highlights First Systemic siRNA Administered in Humans and Quark’s Proprietary siRNA Structures

1/8/2009

Quark Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function

Kidney transplantation to be Quark’s second indication with clinical-stage, systemically administered siRNA product candidate for Delayed Graft Function